What insurance policy changes affect code L74.519?

There are 3 tracked policy changes affecting code L74.519, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code L74.519?

Payers that have issued tracked updates for code L74.519 include: Aetna.

How do I get notified when code L74.519 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code L74.519. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code L74.519?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

L74.519 Insurance Policy Changes

ICD-10 L74.519 is officially defined as "Primary focal hyperhidrosis, unspecified." code L74.519 is referenced in 3 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code L74.519 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Aug 18, 2026Medium impact
Thoracoscopic Sympathectomy (CPB 0310, reviewed 2026-05-20)
Aetna considers thoracoscopic sympathectomy medically necessary for causalgia, for catecholaminergic polymorphic ventricular tachycardia in persons who remain symptomatic despite maximal medical therapy, for long QT syndrome in persons who have failed medical therapy and have frequent implantable cardioverter defibrillator shocks despite medications, for Raynaud's disease, for shoulder-hand syndrome, for some types of visceral pain such as chronic pancreatic pain and cancer-derived visceral abdominal pain, for ventricular tachycardia or ventricular fibrillation storm, for vascular occlusive disease, and for intractable, disabling axillary or palmar primary hyperhidrosis that meets specific criteria. The procedure is considered experimental, investigational or unproven for other indications, including acne vulgaris, craniofacial or plantar hyperhidrosis, and left thoracoscopic sympathectomy for cardiac denervation in persons with heart failure, and it is considered cosmetic for excessive spontaneous facial blushing because that does not result in functional impairment.
Aetna · Identified Aug 18, 2026Medium impact
Iontophoresis (CPB 0229, reviewed 2026-04-23)
Aetna considers iontophoresis medically necessary for delivering local anesthetic before emergent skin puncture or dermatological procedures, for intractable disabling primary focal hyperhidrosis of the axillae, palms or soles when the stated criteria are met, for short-term iontophoretic fentanyl for acute postoperative pain, and for the sweat test by pilocarpine iontophoresis to diagnose cystic fibrosis. The policy lists many other uses as experimental, investigational or unproven, including acetic acid for rotator cuff disease, heel pain and epicondylitis, corticosteroid or NSAID iontophoresis for musculoskeletal disorders, onychomycosis and tinnitus, because of insufficient evidence of its effectiveness. CPT 97033 is covered for iontophoresis only when the selection criteria are met.
Aetna · Identified Aug 15, 2026Medium impact
Hyperhidrosis (CPB 0504, reviewed 2026-08-11)
Aetna considers surgical treatments for primary hyperhidrosis of the axillae, palms or soles medically necessary only for members who are unresponsive or unable to tolerate oral pharmacotherapy, have significant disruption of professional and/or social life from excessive sweating, have topical aluminum chloride or other extra-strength antiperspirants that are ineffective or cause a severe rash, and have failed to adequately respond to iontophoresis. A trial of botulinum toxin can be substituted for iontophoresis in persons with predominantly axillary hyperhidrosis. Laser treatment, microwave therapy, miraDry, pulsed radiofrequency, radiofrequency micro-needling, photodynamic therapy, liposuction-curettage and ultrasound are listed as experimental, investigational or unproven for hyperhidrosis.

Watch L74.519

Get one email when a payer policy names L74.519, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Thoracoscopic Sympathectomy (CPB 0310, reviewed 2026-05-20)

Iontophoresis (CPB 0229, reviewed 2026-04-23)

Hyperhidrosis (CPB 0504, reviewed 2026-08-11)

What insurance policy changes affect code L74.519?

Which payers have updated policy for code L74.519?

How do I get notified when code L74.519 policy changes?

Why do payers change policies for code L74.519?